피엔케이피부임상연구센타
Financials
Valuation Metrics
피엔케이피부임상연구센타's Market Cap is ₩531B. At end of 2025 it was ₩768B. Ranked #1703 of 2,436 in KR market (top 70%), #1026 of 1,649 on KOSDAQ (top 62%), #188 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 80%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 53.09B KRW | KR#1,703/2,436 Sec#188/234 |
| Revenue | 22.56B KRW | KR#2,111/2,436 Sec#151/234 |
| Net Income | 3.74B KRW | KR#1,217/2,436 Sec#84/234 |
| Total Assets | 87.46B KRW | KR#1,848/2,436 Sec#151/234 |
| Net Assets | 80.68B KRW | KR#1,551/2,436 Sec#128/234 |
| Employees | 104 | KR#1,600/2,436 Sec#124/234 |
| Value | ||
| P/E | 14.21x | KR#940/2,436 Sec#58/234 |
| P/B | 0.66x | KR#1,091/2,436 Sec#54/234 |
| P/S | 2.35x | KR#1,906/2,436 Sec#112/234 |
| EV/EBITDA | 17.46x | KR#939/2,436 Sec#55/234 |
| FCF Yield | 9.75% | KR#632/2,436 Sec#25/234 |
| Profitability | ||
| ROE | 4.63% | KR#1,040/2,436 Sec#76/234 |
| ROA | 4.27% | KR#746/2,436 Sec#63/234 |
| Op. Margin | 13.24% | KR#338/2,436 Sec#31/234 |
| Revenue Growth | -3.43% | KR#1,630/2,436 Sec#153/234 |
| Earnings Growth | -37.25% | KR#1,143/2,436 Sec#73/234 |
| Financial Health | ||
| Debt Ratio | 8.41% | KR#8/2,436 Sec#2/234 |
| FCF | 5.18B KRW | KR#897/2,436 Sec#63/234 |
| Cash | 922.8M KRW | KR#2,341/2,436 Sec#226/234 |
| Current Ratio | 8.38x | KR#132/2,436 Sec#33/234 |
| Net Debt/EBITDA | -0.31x | KR#620/2,436 Sec#39/234 |
| Dividend | ||
| Div. Yield | 2.87% | KR#674/2,436 Sec#34/234 |
| Div. Growth | 25.00% | KR#378/2,436 Sec#19/234 |
| Performance | ||
| 1Y Return | -38.79% | KR#1,807/2,436 Sec#160/234 |
| 1M Return | 2.43% | KR#650/2,436 Sec#57/234 |
| From 52W High | -45.23% | KR#990/2,436 Sec#78/234 |
| 1Y MDD | -49.61% | KR#912/2,436 Sec#74/234 |
| Trading | ||
| Volume | 31,140 shares | KR#1,628/2,436 Sec#160/234 |
| Foreign Own. | 1.44% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | 127 KRW | KR#1,317/2,436 Sec#93/234 |
| BPS | 2,800 KRW | KR#1,856/2,436 Sec#147/234 |
Company Info
PNK Skin Clinical Research Center was established in 2010 as Korea's first joint human application testing institution by Daebong LS and a medical college research institute, listing on KOSDAQ in 2020. The company conducts safety and efficacy verification tests for products like cosmetics and health functional foods, while also providing technology and information for new ingredient development and functional cosmetic testing. It leads the market with new protocol development and global-level data reliability, earning technological recognition through a strategic technology cooperation MOU with BASF in 2019.